322-OR: SGLT2 Inhibition Has No Effect on the Counterregulatory Response to Hypoglycemia in Subjects with Type 1 Diabetes (T1D)

Individuals with T1D have an ineffective glucagon response to low glucose levels which predisposes them to episodes of hypoglycemia. SGLT-2 inhibitors (SGLT2i) do not increase and may even reduce hypoglycemia in clinical trials, yet the mechanism is unknown. This trial was conducted to determine if...

Full description

Saved in:

Bibliographic Details
Published in:	Diabetes (New York, N.Y.) Vol. 70; no. Supplement_1
Main Authors:	BOEDER, SCHAFER C., INES, DANIEL G., GIOVANNETTI, ERIN R., HAMIDI, VALA, BURKE, PAIVI M., ARMSTRONG, ADRIENNE, CARTER, LESLIE, PETTUS, JEREMY
Format:	Journal Article
Language:	English
Published:	New York American Diabetes Association 01-06-2021
Subjects:	Clinical trials Diabetes Diabetes mellitus (insulin dependent) Epinephrine Glucagon Growth hormones Hormones Hypoglycemia Insulin Norepinephrine Placebos
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Individuals with T1D have an ineffective glucagon response to low glucose levels which predisposes them to episodes of hypoglycemia. SGLT-2 inhibitors (SGLT2i) do not increase and may even reduce hypoglycemia in clinical trials, yet the mechanism is unknown. This trial was conducted to determine if SGLT2i improve the counterregulatory response (CR) to hypoglycemia. Subjects with T1D (n=22) received 4 weeks of SGLT2i (dapagliflozin 5 mg daily) and 4 weeks of placebo in a double-blind, random-order, cross-over study. After each phase, subjects underwent a hypoglycemic clamp. During 40 min of hypoglycemia (mean serum glucose 49 mg/dL) CR hormones were serially measured. There was no difference between treatment phases in glucagon or other CR hormones during hypoglycemia [Figure]. Mean ± SE (paired two-tailed t-test) during hypoglycemia for SGLT2i vs. Placebo were: Glucagon (15.4 ± 1.8 vs. 14.8 ± 2.1 pg/mL; P = 0.77), Epinephrine (216 ± 34 vs. 200 ± 28 pg/mL; P = 0.46), Norepinephrine (402 ± 39 vs. 381 ± 25 pg/mL; P = 0.51), GH (9.1 ± 1.3 vs. 8.4 ± 1.8 ng/mL; P = 0.60), and Cortisol (11.4 ± 1.1 vs. 10.3 ± 0.9 mcg/dL; P = 0.18). SGLT2i treatment has no effect on the CR hormone response to hypoglycemia in T1D. These data suggest that any reduction in hypoglycemia that occurs with these agents may be due to behavioral changes (e.g., lower insulin doses, less frequent bolusing), rather than a physiologic mechanism.
ISSN:	0012-1797 1939-327X
DOI:	10.2337/db21-322-OR